Dr. Maher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1300 E Marshall St
Richmond, VA 23298Phone+1 804-828-7999
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2014 - 2017- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2011 - 2014
College of Osteopathic Medicine of the PacificClass of 2011
Certifications & Licensure
VA State License 2020 - 2026
AZ State License 2011 - 2021
WA State License 2016 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis Start of enrollment: 2021 Mar 17
Roles: Principal Investigator, Contact
- Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis Start of enrollment: 2021 Mar 11
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design.John Mascarenhas, Keri Maher, Raajit Rampal, Prithviraj Bose, Nikolai Podoltsev
Future Oncology. 2025-03-01 - A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.Keri R Maher, Danielle Shafer, Dale Schaar, Dipankar Bandyopadhyay, Xiaoyan Deng
Cancer Chemotherapy and Pharmacology. 2025-01-17 - 1 citationsClonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia.Graeme F Murray, Ian M Bouligny, Thuy Ho, Juhi Gor, Kyle Zacholski
European Journal of Haematology. 2025-01-01
Press Mentions
Venetoclax-Based Strategies in Patients with Secondary-Type Mutations, Acute Myeloid LeukemiaDecember 12th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
